While other solid tumor cancers have biomarkers in use to help in the diagnosis, predict or prognosticate outcomes, such as the use of prostate specific antigen (PSA) in prostate cancers, urothelial cancer (UC) has no such equivalent markers. This evidence concerns the gene KLK3 and prostate cancer.